



The Midas List

Erika Brown, David Whelan Patricia Huang, 02.13.06

The **Midas List**, which ranks the best dealmakers in high-tech and life sciences, is led this year by a passel of survivors. The folks profiled here have proved their mettle by creating wealth through an economic slump. A lot of the names on last year's list are gone, with the disappearance of the gargantuan valuations of the boom era...

The **Midas List** seeks to identify individuals who deploy venture capital to create wealth for their investors and build valuable, long-lasting companies. Our ranking formula ignores the original amount invested in a deal (as it is often undisclosed), instead weighing most heavily the market capitalization of a venture-backed company at the close of its first day of trading, or the purchase price in an acquisition. A lesser weight is given to the change in value of each investment since going public or being sold. Ranking also depends on a candidate's length of involvement and depth of influence at a startup. Only tech and life sciences companies that have gone public or been acquired within the past five years are considered. Our results are based on extensive reporting and surveys sent to 800 professionals, including angels, bankers, lawyers, recruiters and venture capitalists.

#95

Andrew Senyei, VC

AGE: 55

COMPANY: Enterprise Partners

An MD with an interest in individualized DNA sequencing and gene therapy for heart disease. Recent deals include Adeza Biomedical and NuVasive. Betting on two private companies Ophthonix and vascular biology firm TargeGen based in San Diego.

